Every probiotic strain tells a different scientific story. While many belong to the same bacterial species, their biological properties, mechanism of action and clinical effects can differ significantly. Successful probiotic innovation starts with selecting the right strain – not simply the right species.

For more than 35 years, Probi has been identifying, isolating, developing and commercialising clinically researched proprietary probiotic strains that help brands create differentiated health products backed by meaningful scientific evidence.

From microbiome discovery and strain selection to pre-clinical and clinical validation, formulation support and commercial manufacturing, every stage of development is driven by one objective: delivering probiotic solutions our customers can trust, and consumers can rely on.

Explore our probiotic strain portfolio

Every Probi strain has its own scientific profile, clinical documentation where applicable and technical specifications.

• Lactiplantibacillus plantarum 299v (LP299V®)

• Lactiplantibacillus plantarum HEAL9 (HEAL9®)

• Lactiplantibacillus plantarum HEAL19 (HEAL19™)

• Lacticaseibacillus paracasei 8700:2 (L. paracasei 8700:2™)

• Streptococcus salivarius K12 (BLIS K12™)

• Streptococcus salivarius M18 (BLIS M18™)

• Lacticaseibacillus rhamnosus 271 (Rham271™)

• Lacticaseibacillus rhamnosus 271h (Rham271h™)

• Lactiplantibacillus plantarum 6595 (LP6595)

Additional strains are available across our broader portfolio to support a range of formulation and product development needs.

Strain selection defines product success

Scientific consensus agrees that probiotic benefits are strain-specific. Clinical evidence generated for one probiotic strain cannot be applied to another.

Every probiotic strain possesses its own set of characteristics that influence how it survives manufacturing, interacts with the microbiome and delivers measurable health outcomes.

For manufacturers, this makes strain selection one of the most important decisions in product development.

Documented strains help support:

• Product efficacy

• Regulatory confidence

• Manufacturing consistency

• Consumer trust

• Long-term brand credibility

At Probi, scientific validation is never an afterthought – it is central to our innovation programme.

Built on science, but proven through research

Developing clinically documented probiotic strains takes years of research and scientific expertise.

Probi combines microbiology, molecular biology, omic technologies and sequencing, clinical research and manufacturing expertise to identify strains with documented functionality and commercial relevance. Every strain within our portfolio undergoes a comprehensive scientific development process that includes:

Discovery & identification

Potential strains are isolated, identified and genetically characterised to establish their unique biological profile

Functional evaluation

Laboratory research investigates how each strain interacts with biological systems and explores its potential mechanisms of action.

Clinical validation

Human clinical studies evaluate safety, efficacy and targeted health outcomes using robust study designs

Manufacturing assessment

Each strain is evaluated for stability, viability and performance throughout production, formulation and shelf life.

Scientific documentation

Clinical evidence and technical documentation provide the foundation for product development and regulatory evaluation.

By combining these disciplines, Probi transforms microbiome science into commercially successful and impactful health solutions.